Clinical Trials Logo

Clinical Trial Summary

To evaluate whether the efficacy of the abiraterone acetate tablets (I) is comparable to that of the ZYTIGA®) by comparing the serum testosterone concentrations on Day 9 and/or Day 10 after oral administration of the two formulations in patients with metastatic castration-resistant prostate cancer (mCRPC).

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT04862091
Study type Interventional
Source Jiangsu HengRui Medicine Co., Ltd.
Contact Yuanyuan Huang
Phone +86 18036618522
Email [email protected]
Status Not yet recruiting
Phase Phase 2
Start date April 25, 2021
Completion date October 25, 2021

See also
  Status Clinical Trial Phase
Completed NCT01977651 - A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide Phase 4
Recruiting NCT04015622 - PROstate Cancer TReatment Optimization Via Analysis of Circulating Tumour DNA Phase 2
Not yet recruiting NCT04691804 - A Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Phase 3
Completed NCT03896984 - Descriptive Analysis of Clinical Outcomes in Patients With Prostate Gland Cancer, Which Spreads to Other Parts of the Body, Who Were Treated First With Novel Anti-hormone Therapy Followed by a Second Line Treatment With Novel Anti-Hormone Therapy or RadIum-223 (Xofigo).
Not yet recruiting NCT04587427 - A Study to Learn More About How Radium-223 is Being Used With Other Treatments in European Patients Who Have Not Received Radium-223 Before
Completed NCT03074032 - Safety, Tolerability and Pharmacokinetics of ONC1-0013B in Patients With Progressive Metastatic Castration-resistant Prostate Cancer Phase 1
Recruiting NCT03071328 - INJECT: A Pilot Study of Intra-tumoral Injections in Metastatic Urological Cancers Early Phase 1
Completed NCT03030885 - Use of an Experimental Radiopharmaceutical (131I-MIP-1095) in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Phase 1
Terminated NCT03712930 - Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency Phase 2
Completed NCT03811652 - A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors Phase 1
Active, not recruiting NCT04089553 - An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer Phase 2
Temporarily not available NCT04825652 - 177Lu-PSMA-617 Managed Access Program for mCRPC Patients